newsfilter
← Latest News
GlobeNewswire·

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

BRIDGEWATER, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and